Chemotherapy Awakens Dormant Cancer Cells Through Neutrophil Traps

This groundbreaking study reveals a concerning paradox in cancer treatment: chemotherapy drugs designed to kill cancer cells may actually awaken dormant tumor cells and promote metastasis. The research has significant implications for understanding why some patients experience cancer recurrence years after successful treatment.

Using breast cancer models, researchers investigated how disseminated tumor cells (DTCs) that remain dormant in distant organs can suddenly reactivate. They developed a sophisticated tracking system called DormTracer to monitor these dormant cells in real-time and discovered that common chemotherapy drugs like doxorubicin and cisplatin enhanced both proliferation and lung metastasis of previously dormant breast cancer cells.

The mechanism involves a cascade of cellular events: chemotherapy induces senescence in fibroblasts (connective tissue cells), which then secrete proteins that promote formation of neutrophil extracellular traps (NETs). These web-like structures, normally part of immune defense, remodel the extracellular matrix and create an environment that stimulates dormant cancer cells to proliferate and spread.

Most encouragingly, the researchers identified a potential solution. When they combined senolytic drugs (dasatinib and quercetin) with doxorubicin, they successfully prevented dormant cell reactivation and suppressed metastatic relapse. Senolytics are compounds that selectively eliminate senescent cells, breaking the chain of events that leads to cancer cell awakening.

This research provides direct evidence for chemotherapy-induced dormancy awakening and offers a mechanistic explanation for treatment-related metastasis, potentially leading to improved combination therapies that maintain chemotherapy's benefits while preventing its unintended consequences.